Study Sites
The ReMEDy2 trial is expected to recruit approximately 350 participants who experienced an eligible acute ischemic stroke at up to 75 clinical trial centers in the United States.
The safety and effectiveness of DM199 for the treatment of acute ischemic stroke or cardio-renal disease has not been established and is limited to investigational use only.